1.2500
-0.0700
(-5.30%)
At close: January 30 at 4:00:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-62,564.0000
-81,228.0000
-94,498.0000
-57,116.0000
-33,659.0000
Investing Cash Flow
16,340.0000
110,859.0000
49,438.0000
-10,443.0000
-146,322.0000
Financing Cash Flow
49,421.0000
48,616.0000
171.0000
1,929.0000
330,866.0000
End Cash Position
43,829.0000
125,626.0000
47,379.0000
92,268.0000
157,898.0000
Capital Expenditure
-76.0000
-407.0000
-11,614.0000
-7,926.0000
-727.0000
Issuance of Capital Stock
--
48,170.0000
--
--
349,921.0000
Free Cash Flow
-62,640.0000
-81,635.0000
-106,112.0000
-65,042.0000
-34,386.0000
12/31/2020 - 10/9/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SPRB Spruce Biosciences, Inc.
0.3661
-0.71%
PRLD Prelude Therapeutics Incorporated
1.1900
+3.93%
PMVP PMV Pharmaceuticals, Inc.
1.4400
+0.70%
CCCC C4 Therapeutics, Inc.
3.6800
+2.51%
ANTX AN2 Therapeutics, Inc.
1.1700
-0.85%
CGEM Cullinan Therapeutics, Inc.
10.98
-2.40%
TRML Tourmaline Bio, Inc.
16.40
+0.43%
ZURA Zura Bio Limited
1.7600
+1.73%
SNSE Sensei Biotherapeutics, Inc.
0.4725
+0.32%
FHTX Foghorn Therapeutics Inc.
4.3400
+9.05%